[{"address1": "321 Arsenal Street", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "339 217 0161", "website": "https://www.iteostherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 173, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michel  Detheux Ph.D.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1120393, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew A. Call M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 725481, "exercisedValue": 0, "unexercisedValue": 1074044}, {"maxAge": 1, "name": "Dr. David  Feltquate M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "totalPay": 774444, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Gall", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 648001, "exercisedValue": 0, "unexercisedValue": 1259823}, {"maxAge": 1, "name": "Dr. Yvonne  McGrath Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Adi  Osovsky", "title": "Executive Vice President of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Brantegem", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.97, "open": 7.91, "dayLow": 7.73, "dayHigh": 8.04, "regularMarketPreviousClose": 7.97, "regularMarketOpen": 7.91, "regularMarketDayLow": 7.73, "regularMarketDayHigh": 8.04, "payoutRatio": 0.0, "beta": 1.393, "forwardPE": -1.3350427, "volume": 1159849, "regularMarketVolume": 1159849, "averageVolume": 755695, "averageVolume10days": 2461010, "averageDailyVolume10Day": 2461010, "bid": 5.77, "ask": 9.99, "bidSize": 2, "askSize": 2, "marketCap": 298918368, "fiftyTwoWeekLow": 4.8, "fiftyTwoWeekHigh": 18.7, "priceToSalesTrailing12Months": 8.5405245, "fiftyDayAverage": 6.6918, "twoHundredDayAverage": 9.2371, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -216397664, "profitMargins": 0.0, "floatShares": 25138611, "sharesOutstanding": 38273800, "sharesShort": 2531510, "sharesShortPriorMonth": 1829148, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0661, "heldPercentInsiders": 0.01135, "heldPercentInstitutions": 1.03996, "shortRatio": 4.93, "shortPercentOfFloat": 0.0851, "impliedSharesOutstanding": 38273800, "bookValue": 14.722, "priceToBook": 0.53049856, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -130811000, "trailingEps": -3.05, "forwardEps": -5.85, "enterpriseToRevenue": -6.183, "enterpriseToEbitda": 1.456, "52WeekChange": -0.5682697, "SandP52WeekChange": 0.12250078, "quoteType": "EQUITY", "currentPrice": 7.81, "targetHighPrice": 13.0, "targetLowPrice": 8.0, "targetMeanPrice": 10.4, "targetMedianPrice": 10.0, "recommendationMean": 2.16667, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 520368992, "totalCashPerShare": 13.596, "ebitda": -148648992, "totalDebt": 5053000, "quickRatio": 13.78, "currentRatio": 14.133, "totalRevenue": 35000000, "debtToEquity": 0.897, "revenuePerShare": 0.827, "returnOnAssets": -0.14541, "returnOnEquity": -0.23684, "grossProfits": 35000000, "freeCashflow": -47053876, "operatingCashflow": -99545000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -4.28306, "financialCurrency": "USD", "symbol": "ITOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "shortName": "iTeos Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1747438899, "regularMarketTime": 1747425601, "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "earningsTimestamp": 1745872200, "earningsTimestampStart": 1754483400, "earningsTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.05, "epsForward": -5.85, "epsCurrentYear": -2.93105, "priceEpsCurrentYear": -2.6645741, "fiftyDayAverageChange": 1.1181998, "fiftyDayAverageChangePercent": 0.1671, "twoHundredDayAverageChange": -1.4270997, "twoHundredDayAverageChangePercent": -0.15449652, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "2.2 - Buy", "cryptoTradeable": false, "longName": "iTeos Therapeutics, Inc.", "regularMarketChangePercent": -2.0075264, "regularMarketPrice": 7.81, "marketState": "CLOSED", "postMarketChangePercent": 3.96927, "postMarketPrice": 8.12, "postMarketChange": 0.31, "regularMarketChange": -0.15999985, "regularMarketDayRange": "7.73 - 8.04", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 755695, "fiftyTwoWeekLowChange": 3.0099998, "fiftyTwoWeekLowChangePercent": 0.62708324, "fiftyTwoWeekRange": "4.8 - 18.7", "fiftyTwoWeekHighChange": -10.890001, "fiftyTwoWeekHighChangePercent": -0.582353, "fiftyTwoWeekChangePercent": -56.826973, "exchange": "NGM", "messageBoardId": "finmb_663087242", "exchangeTimezoneName": "America/New_York", "displayName": "iTeos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]